Moreover, c-myc is involved in AML cells resistance to chemotherapy and therefore identifying new drugs able to downmodulate c-myc levels might greatly improve the therapeutic approach of AML relapsing patients42,43. The gene discussed is MYC; the disease is acute myeloid leukemia.